3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
32
Sarcoma
29
Neoplasm Metastasis
17
Ovarian Neoplasms
10
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Kidney Neoplasms
6
Recurrence
5
Lung Neoplasms
5
Liposarcoma
5
Thyroid Neoplasms
4
Melanoma
4
Leiomyosarcoma
4
Hemangiosarcoma
4
Urinary Bladder Neoplasms
3
Solid Tumors
3
Pancreatic Neoplasms
3
Neurofibrosarcoma
3
Glioblastoma
3
Gastrointestinal Stromal Tumors
3
Chondrosarcoma, Extraskeletal Myxoid
3
Advanced Cancers
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solitary Fibrous Tumors
2
Small Cell Lung Carcinoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdomyosarcoma
2
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Refractory or Recurrent Solid Tumor
×
pazopanib
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled